Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improved foamy virus vectors with minimal viral sequences.

Grant Trobridge1, Neil Josephson, George Vassilopoulos

  • 1Department of Medicine, Division of Hematology, University of Washington, Seattle, Washington 98195, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|September 17, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptional analysis of BMP2 and BMP6 in patients with newly diagnosed multiple myeloma.

Oncology letters·2025
Same author

Use of a Foamy-Virus Vector System to Produce an 'Off-the-Shelf' Fcγ-CR-T Cell Product for the Treatment of Haematological and Solid Tumour Malignancies.

Immunology·2025
Same author

Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS).

Cancers·2025
Same author

Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab.

Dermatology practical & conceptual·2025
Same author

Angiogenesis and multiple myeloma: Exploring prognostic potential of adrenomedullin.

Cancer medicine·2024
Same author

Prospective study of complement activation and thromboinflammation within sickle cell disease and its complications.

HemaSphere·2024
Same journal

Long-term functional synaptic integration of genome-edited retinal organoids in a primate model of macular degeneration.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Nox1/4 inhibitor Setanaxib treatment ameliorates cardiac function in mouse models of Duchenne Muscular Dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

HSP90α-USP7-DNMT1 Axis Drives Hepatocellular Carcinoma Recurrence After Microwave Ablation by Disrupting ACSS3-Mediated Propionate Metabolism.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Cell-penetrating asymmetric siRNA targeting MyD88 suppresses inflammasome-driven ocular degeneration and angiogenesis.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Targeting vaccine fusion proteins to APCs increases immunogenicity of adenoviral and mRNA-LNP vaccines.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Discovery of circadian clock activators with anti-obesity efficacy via suppression of adipocyte development and hypertrophy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
See all related articles

High-titer foamy virus (FV) vectors for gene therapy were developed using a transient cotransfection system. These deleted FV (deltaphi) vectors achieve high titers with minimal viral genome, enabling large transgene delivery.

Area of Science:

  • Gene Therapy
  • Virology
  • Molecular Biology

Background:

  • Foamy virus (FV) vectors are promising for gene therapy.
  • Current FV vectors have limitations, including large genomes and low production titers.

Purpose of the Study:

  • To develop a high-titer FV vector system with a minimal genome for gene therapy.
  • To overcome limitations of existing FV vectors for efficient gene delivery.

Main Methods:

  • Developed a transient cotransfection system using four plasmids for Gag, Pol, Env, and vector expression.
  • Engineered deleted foamy (deltaphi) vectors with deletions in non-essential genes and LTR U3 region.
  • Introduced stop codons in remaining gag sequences to prevent viral peptide expression.

Related Experiment Videos

Main Results:

  • Achieved helper-free, unconcentrated deltaphi vector titers exceeding 10(5) transducing units/ml.
  • Concentrated deltaphi vector stocks reached titers over 10(7) transducing units/ml.
  • Demonstrated utility for large therapeutic genes with a 9.2-kb transgene cassette.

Conclusions:

  • The transient cotransfection system enables high-titer production of deltaphi vectors.
  • These deltaphi vectors are suitable for gene therapy applications, including delivery of large therapeutic genes.
  • The engineered vectors minimize viral components, enhancing safety and efficiency.